In people who struggle with weight, these signals can be weaker than they should be the body may not produce enough GLP-1, or the brain may not respond to it with the same sensitivity
[DOI] [PMC free article] [PubMed] 33.Navarro-Gonzlez J.F., Mora-Fernndez C., De Fuentes M.M., Garca-Prez J
Your doctor should assess several factors before approving discontinuation, including your current weight status and trajectory, the presence and control of obesity-related comorbidities (type 2 diabetes, hypertension, sleep apnea, cardiovascular disease), your readiness and capacity to implement intensive lifestyle modifications, available support systems and resources, and your history of weight cycling or previous weight loss attempts
Oral semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: long-term cost-effectiveness analyses based on the PIONEER clinical trial programme
January 10, 2024: We are offering updates about Mounjaro and Ozempic MDL class action lawsuits